

# Nanoparticles for Targeted Cancer Therapy: Mechanisms, Benefits, and Challenges

Ayan Sarkar<sup>1\*</sup>; Anusuya Nandi<sup>2</sup>; Diptendra Bhattacharya<sup>3</sup>

<sup>1,2,3</sup>Department of Pharmacy, Guru Nanak Institute of Pharmaceutical Science and Technology, 157/F, Nilgunj Rd, Sahid Colony, Panihati, Khardaha, West Bengal 700114

Corresponding Author: Ayan Sarkar<sup>1\*</sup>

Publication Date: 2026/06/06

**Abstract:** Cancer, a worldwide major cause of mortality, treated with conventional treatments often exhibits limited efficacy and significant side effects. Nanotechnology has been recognized as a viable area for improving cancer treatment recently. The special properties of nanoparticles and their ability to interact with biological systems at the nanoscale have paved the way for targeted cancer therapy, enabling precision medicine approaches. This abstract presents an outline of the use of nanotechnology in targeted cancer therapy.

First, it highlights the drawbacks of conventional cancer therapies that includes chemotherapy and radiation therapies, which often lack specificity and result in damage to the healthy tissues. It then introduces the concept of nanotechnology as a means that overcome these limitations. Utilizing nanoparticles as means of administration for anticancer agents is a key aspect of targeted therapy. Nanoparticles can be engineered to possess specific characteristics, size, shape, surface charge, and functionalization are a few characteristics, which allow them to selectively target cancer cells sparing healthy tissues. Various types of nanoparticles, including liposomes, polymeric nanoparticles, and metallic nanoparticles are discussed in relation due of their special characteristics and applications in cancer targeted therapy.

This abstract delves into the strategies employed for targeted drug delivery using nanotechnology. Active target selection and passively targeting targets using enhanced permeability and retention (EPR) are two of these techniques, impact using ligands or antibodies, and stimuli-responsive mechanisms that disperse medication in response to particular conditions within the tumor microenvironment. The abstract additionally explores the role of nanotechnology in imaging and diagnostics for cancer detection and monitoring. Nanoparticles can serve as contrast agents for several imaging modalities, similar to MRI (magnetic resonance imaging) and CT (computed tomography), and others and emission based imaging example PET (positron emission tomography), enabling early and accurate diagnosis, as well as real-time monitoring of treatment response.

**Keywords:** Nanoparticles, Nano Medicine, Drug Delivery, Cancer Therapy.

**How to Cite:** Ayan Sarkar; Anusuya Nandi; Diptendra Bhattacharya (2026) Nanoparticles for Targeted Cancer Therapy: Mechanisms, Benefits, and Challenges. *International Journal of Innovative Science and Research Technology*, 11(5), 3343-3354. <https://doi.org/10.38124/ijisrt/26may2014>

## I. INTRODUCTION

### ➤ Cancer Overview:

A condition called cancer results from an uncontrolled proliferation and diffusion of anomalous cells within the organism. These distorted cells have the capacity to spread by way of blood or lymphatic circulation. Leading to tumor formation and infiltration into neighbouring tissue. [1, 2]

Cancer are of several types. The causes of cancer may vary, but different factors that might raise the possibility of developing cancer are often accompanied with genetic changes; exposures of carcinogens; and/or certain infections. Cancer patients should be aware that diagnosis tailored

therapies are available for their individual needs based on factors like the type of cancer they have and how far along it is. Treatment could incorporate strategies like immunotherapy or targeted drug therapy as well as conventional therapies such as radiation therapy and/or surgery in effectively fighting cancers progression. [1, 2]

New or a novel system of treating cancer cell has been introduced in spite of the existing processes to increase target specific drug delivery. One such process is through 'Nanotechnology'. The current review focuses into the process of cancer prevention and treatment of cancer cells through nanotechnology. [1, 2]

➤ *The Genesis of a Cancer Cell:*

A healthy cell transforms into a cancer cell after one or more DNA mutations. They are frequently brought on by exposure to viruses or other carcinogens. They can also be hereditary as well. [3, 4]

Cancer cells typically start as a single abnormal cell that undergoes uncontrolled growth and division. They can form a mass or tumour as the abnormal cells continue to divide. Cancer cells have the ability to metastasize *i.e.* they travel from one region into the body to another with the circulatory system. There are two broad categories of significant genetic changes: [3, 4]

- *Proto-oncogene Activation into Oncogenes.*

Genes called proto-oncogenes usually regulate cell division, apoptosis, and differentiation; nevertheless, they can be altered by carcinogens or viruses to become malignant oncogenes.

- *Inactivation of Tumour Suppressor Genes.*

Notably ordinary cells are equipped with unique genetic material designed to counteract the development of fatal mutations linked with cancers at various stages. These tumor suppressor (anti-oncogene) genes serve a crucial role in mitigating risks for individuals from multiple malignancies.

➤ *Introduction to Nanotechnology:*

Nanotechnology has revolutionized the subject of medicine, incorporating drug delivery methods. Targeted drug therapy or precision medicine is a treatment strategy that involves the use of drugs that specifically target cancer cells or other diseased cells leaving healthy cells unharmed. Medical research continues at an impressive pace with advancements like nanoparticle technology revolutionising targeted drug delivery methods. Measuring between one and one hundred nanometres in size these particles provide a critical avenue for drugs designed specifically for target cells. Nanoparticles offer remarkable advantages relevant to medical treatment including overcoming obstacles like the blood brain barrier - traditionally a hurdle difficult to surpass when administering medication effectively. Furthermore. Scientists can configure these tiny particles by adding ligands or antibodies on their exterior surface so they may accurately target select cells. [2, 3, 5]

Targeted medication therapy is a potential strategy for treating the variety of ailments including cancer made possible by nanotechnology. The efficacy of a drug can be improved and adverse effects can be decreased by using

nanoparticles to target certain cells shielding the drug from deterioration and releasing it in a regulated manner at the specific site. [3, 4]

For an example, nanoparticles can be design to target carcinogenic cells in cancer therapy by fixing antibodies that recognise definite proteins on the surface of the cells. The drug then stop the release of cancer cells when the nanoparticles make an active contact with the target cells. [3, 4]

➤ *Mechanisms of Cellular Targeting of Cancer Drugs:*

- *Active Targeting:*

Active targeting approaches can enhance the specificity and efficacy of cancer treatments by selectively delivering therapeutic agents to cancer cells. They hold great potential for improving the precision and effectiveness of cancer therapies while minimizing the toxic effects on healthy tissues. [9, 10]

- *Antibody-Based Targeting:*

Antibodies refer to proteins that can differentiate and connect with specific molecules recognized as antigens located on cancer cells' exteriors. For research purposes. Scholars may create or utilize monoclonal antibodies depending on their preference & target these antigens selectively. These antibodies can be attached to therapeutic drugs or imaging agents, allowing them to specifically target and bind to cancer cells, leading to localized treatment or enhanced imaging. [11, 12]

- *Ligand-Receptor Targeting:*

Cancer cells often over express specific receptors on their surface. Ligands like small molecules or peptides can be designed or selected to bind to these receptors with high affinity and specificity. Therapeutic drugs or imaging agents can be conjugated to these ligands, enabling their selective delivery to cancer cells. [11, 12]

- *Nanoparticle-Based Targeting:*

Nanoparticles are tiny particles typically ranging from 1 to 100 nanometers in size. They can be engineered to carry therapeutic drugs or imaging agents and are functionalized with molecules that specifically recognize cancer cells. These targeting molecules can be antibodies, peptides, or other ligands that bind to receptors or antigens on the cancer cell surface. The nanoparticles can be designed to release their cargo specifically within cancer cells or in response to certain stimuli found in the tumor microenvironment. [11, 12]




Fig 1 Active and Passive Targeting of Nanoparticles in Tumor Tissue

➤ **Cell-Based Targeting:**

Modified immune cells or other types of cells are engineered to recognize and target cancer cells in this approach. Chimeric antigen receptor (CAR) T-cell therapy for example involves modifying a patient's own T cells to express CARs. CARs are receptors that specifically recognize cancer cell antigens. These CAR T cells are then infused back into the patient, where they can seek out and destroy cancer cells. [11, 12]

➤ **Passive Targeting:**

During the late 1980s, it was discovered that cancer cells biasedly accumulated certain macromolecules. Passive targeting is a type of targeted drug delivery system that relies on the unique properties of cancer cells to selectively deliver drugs to tumours while minimizing damage to healthy tissues. Passive targeting takes advantage of the fact that tumour blood vessels are leaky and have a poor lymphatic drainage system in cancer, which allows drugs to accumulate preferentially in the tumour tissue. The basic principle of passive targeting is to encapsulate a drug in a carrier system, such as liposomes or nanoparticles that can circulate in the bloodstream and extravasate into the tumour tissue through the leaky blood vessels. The carrier prevents the medication from being broken down and eliminated by the body, and through the increased permeability and retention (EPR) action, it can also increase its accumulation in the cancer tissue. [6, 7, 8]

**II. CANCER TREATMENT USING NANOPARTICLES**

Nanoparticles are being developed as a promising approach to increase the effectiveness and lessen the negative effects of current therapies in cancer. [13]

Nanoparticles can be designed to have specific properties that helps them to enable and selectively bind to cancer cells or tumor vasculature. Nanoparticles can be designed to carry a variety of therapeutic agents, like chemotherapeutic drugs, small interfering RNA (siRNA), or proteins that can kill cancer cells or can inhibit the growth of tumor. [13]

The deep tissue penetration of NPs is said to promote their enhanced permeability and retention (EPR) function. The surface features also influence bioavailability and half-life by overcoming epithelial fenestration. Inhibiting opsonisation and evading immune system clearance are two examples of PEG-coated nanoparticles. It is also possible to accelerate the release rate of drugs or active substances altering the particle polymer characteristics. The distinctive qualities of NPs are used to regulate their therapeutic effectiveness in the detection and treatment of cancer. [13]

➤ **Synthesis of Nanoparticles (NP):**

NPs can be of various shapes, sizes, and topologies. To achieve this, several synthetic procedures are used. These

methods might essentially be classified in two types of categories:

- Bottom-up approaches and
- Top-down approaches. [14]

➤ *Bottom – up approaches:*

This is the combination of nanoparticles for the application in malignant growth that includes the gathering of more modest units, similar to particles, atoms, or sub-atomic bunches, to frame nanoparticles for certain ideal properties. This approach permits exact command over the size, shape, arrangement, and surface properties of the nanoparticles. Here are a portion of the overall outlines of the perspective in the combination of nanoparticles for disease:

- Design and selection of the building blocks: The first step is to the design the appropriate building blocks that will self-assemble to form nanoparticles with the desired characteristics.
- Self-assembly: The selected building blocks are then allowed to self-assemble under some specific conditions, like temperature, pH, or solvent conditions.
- Template-assisted synthesis: In several cases, a particular template can be used to guide the assembly process that control the size and shape of the nanoparticles.
- Surface modification: As the nanoparticles are formed, their surfaces can also be modified, for the enhancement of the stability, biocompatibility, and targeting capabilities.
- Characterization: Throughout the whole synthesis process, the nanoparticles are characterized to assess their proper size, shape, surface properties, stability, and drug-loading capacity. [14]

➤ *Top-Down Approach:*

The top-down approach of nanoparticles for malignant growth applications includes the decrease or fracture of mass materials to get nanoparticles with wanted properties. With regards to disease, these nanoparticles can be intended to convey drugs, upgrade imaging, or target explicit malignant growth cells. [15]

Here are a portion of the overall outlines of the perspective in the combination of nanoparticles for disease:

- Selection of bulk material: The initial step is to pick a reasonable mass material that can be decreased to nanoparticles
- Size reduction: Various techniques can be employed to reduce the size of the bulk material and obtain nanoparticles
- Surface modification: After obtaining the desired nanoparticles, their surfaces are typically modified to enhance their stability, biocompatibility, and targeting capabilities.
- Functionalization: Nanoparticles can be functionalized to serve specific purposes in cancer therapy
- Characterization: Throughout the synthesis process, the nanoparticles are characterized to assess their size, shape,

surface properties, stability, and drug-loading capacity [15]

### III. ORGANIC NANOPARTICLES

➤ *Polymeric Nanoparticles:*

Polymeric nanoparticles have gathered huge interest in the field of disease research because of their adaptable properties and likely applications in malignant growth analysis, imaging, and treatment. These nanoparticles are regularly produced using biocompatible and biodegradable polymers and can be designed to have explicit attributes for designated conveyance of anticancer medications, imaging specialists, or hereditary materials. [16, 17]

➤ *Dendrimers:*

Dendrimers are a class of profoundly expanded, tree-like polymers with a clear cut structure and nanoscale aspects. Their special engineering, which comprises of a center, different layers of branches, and terminal useful gatherings, makes them alluring for different applications in malignant growth research. Dendrimers can serve as carriers for delivering anticancer drugs to tumor sites. Dendrimers can be functionalized with imaging agents, such as fluorescent dyes, quantum dots, or magnetic nanoparticles, for cancer detection and imaging. Dendrimers offer unique advantages in terms of their precise structure, multivalency, and surface functionalization capabilities, which can be tailored for specific cancer-related applications. [18, 19]

➤ *mAb Nanoparticles:*

Monoclonal antibody (mAb) nanoparticles, otherwise called antibody based nanoparticles, are a kind of nanoparticle that consolidates monoclonal antibodies as key parts. These nanoparticles join the explicitness and focusing on abilities of monoclonal antibodies with the special properties of nanoparticles, offering possible applications in malignant growth conclusion, imaging, and treatment.

mAb nanoparticles can be designed to explicitly target malignant growth cells or explicit receptors overexpressed on growth cells.

Monoclonal antibodies are regularly utilized in disease immunotherapy to target explicit atoms engaged with cancer development, safe avoidance, or angiogenesis. [20, 21]

➤ *Liposomes:*

Liposomes are round vesicles made from lipid bilayers that eagerly seem to be the development of cell layers. By virtue of their biocompatibility, biodegradability, and capacity to typify both hydrophilic and hydrophobic substances, liposomes have been comprehensively thought of and used in different applications in undermining improvement research. Liposomes can be intended to have a long scattering time in the dissemination framework, taking into account extended drug assortment in developments through the superior immersion and upkeep (EPR) influence. Liposomes have been examined as carriers for conveying nucleic acids, similar to DNA or RNA, for dangerous development quality treatment. [22, 23]




Fig 2 Types of Organic and Inorganic Nanoparticles in Cancer Treatment

**IV. INORGANIC NANOPARTICLES**

➤ *Carbon Nanoparticles:*

Carbon nanoparticles, generally carbon-based nanoparticles or carbon nanomaterials, are nanoscale particles made fundamentally out of the carbon atoms. These nanoparticles show one of a kind physical, synthetic, and optical properties, making them alluring for many applications in fields like gadgets, energy, medication, and ecological remediation. Carbon nanoparticles have a large number of uses and hold extraordinary potential for headways in different fields. [26, 27]

➤ *Quantum Dots:*

Quantum dots (QDs) are nanoscale semiconductor particles typically composed of groups of atoms from the periodic table's IV-VI or III-V groups. They show special optical and electronic properties because of their quantum repression impacts, wherein the way of behaving of electrons and openings is restricted in each of the three aspects, bringing about discrete energy levels.

The novel properties of quantum spots make them significant in a great many applications, including imaging, diagnostics, detecting, energy, and optoelectronics. [28, 29]

➤ *Magnetic Nanoparticles:*

MNPs are nanoscale particles that show attractive properties. They are regularly made out of attractive materials like iron, cobalt, nickel, or their combinations.

Attractive nanoparticles have attractive properties, like ferromagnetism, paramagnetism, or superparamagnetism, contingent upon their synthesis, size, and temperature.

MNPs have been widely examined and used in different biomedical applications. They are generally utilized as differentiation specialists in attractive reverberation imaging (X-ray) to upgrade picture contrast and work on analytic abilities. [30, 31]

➤ *Calcium Phosphate Nanoparticles:*

Calcium phosphate nanoparticles (CaP NPs) are nanoscale particles made principally out of calcium and phosphate particles. They are much of the time shaped by the precipitation of calcium and phosphate salts in fluid arrangements.

Calcium phosphate nanoparticles are biocompatible and non-harmful, making them reasonable for different biomedical applications.

Calcium phosphate nanoparticles have been widely read up as transporters for drug conveyance. [32, 33]

➤ *Drug Resistance Overcoming Mechanism of NPs:*

One of the prevailing hurdles in treating and managing cancer is drug resistance. This challenge permeates across all variants and existing therapies for the disease. When illnesses grow resistant to pharmaceutical treatments, drug resistance is a condition that arises. Two types of drug resistance can be distinguished: 2) Taught; and 3) Natural. Genes that regulate cell growth or death typically already have mutations that

provide innate resistance. The form of resistance known as "acquired resistance" develops after a specific anti-tumor therapy and may be triggered by the emergence of additional mutations or modifications in the TME as a result of therapy. [34]

Because of their ability to overcome therapeutic resistance for cancer, nanoparticles excellent ability to co-encapsulate several medicinal compounds.

- *Efflux Transporters*

Play a significant role in drug resistance by actively pumping anticancer drugs out of cancer cells, reducing their intracellular concentration and effectiveness. Targeting these efflux transporters can help overcome drug resistance and improve the efficacy of chemotherapy. [35]

- *Here are Some Strategies Used to Target Efflux Transporters:*

- ✓ *Inhibition of Efflux Transporters:*

Efflux transporter inhibitors can hinder the activity of these pumps, obstructing the removal of anticancer drugs from cancer cells. Scientists have identified multiple compounds as efflux transporter blockers, including verapamil, cyclosporine A, and quinidine. These inhibitors can be administered in combination with chemotherapy drugs to increase their intracellular concentration and overcome resistance. [35]

- ✓ *Co-Delivery with Efflux Transporter Inhibitors:*

In combination therapy approaches, efflux transporter inhibitors can be co-delivered along with anticancer drugs using drug delivery systems such as nanoparticles. By encapsulating both the inhibitor and the anticancer drug within the same carrier, the inhibitor can enhance the intracellular accumulation of the drug, improving its effectiveness against drug-resistant cancer cells. [35]

- ✓ *Efflux Transporter Gene Silencing:*

RNA interference (RNAi) approaches can be used to target efflux transporter genes such as P-gp or MRP. One can create short hairpin RNA shRNA or siRNA to precisely inhibit the production of these transporters. This approach can decrease the activity of efflux transporters, increasing the intracellular drug concentration and overcoming resistance. [35]

- ✓ *Modulation of Transporter Expression:*

To decrease the efflux transporter gene expression levels, experts have identified various techniques. These methods include using gene expression modulators like transcription factors or epigenetic modifiers. Moreover, certain chemotherapeutic medicines or targeted therapies can be used to minimize the expression of these transporters or sensitize resistant cells to chemotherapy. [35]

- ✓ *Targeted Delivery to Bypass Efflux Transporters:*

Efflux transporters are mainly localized on the cell membrane. By utilizing targeted drug delivery systems, such as nanoparticles functionalized with specific ligands or

antibodies, anticancer drugs can be delivered directly to cancer cells while bypassing the efflux transporters on the cell surface. This approach allows for enhanced drug accumulation within cancer cells and circumvents the efflux mechanism. [35]

- *Targeting Apoptotic Pathway:*

Apoptosis is a customized cell demise strategy that is fundamental for safeguarding tissue homeostasis and disposing of harmed or unnecessary cells. Dysregulation of apoptotic pathways can add to malignant growth advancement and protection from treatment. Targeting apoptotic pathways can be a promising approach to induce cancer cell death and overcome treatment resistance. [36]

- *Here are Some Strategies for Targeting Apoptotic Pathways:*

- ✓ *Activation of Intrinsic Apoptotic Pathway:*

Pro-apoptotic and anti-apoptotic proteins, such as those in the Bcl-2 family, must coexist in balance in order to manage the intrinsic apoptotic pathway, which results in its activation. Following are several methods to open this passage way. [36]

- **BH3 mimetics:** BH3 mimetics are little particles that resemble favorable to apoptotic proteins in the Bcl-2 family. They trigger apoptosis by forestalling favorable to apoptotic proteins like Bax and Bak from permeabilizing the mitochondrial layer and inciting cell death. By obstructing against apoptotic proteins, for example, Bcl-2 and Bcl-xL, BH3 mimetics achieve this. [36]
- **Inhibition of anti-apoptotic proteins:** Restraining explicit enemy of apoptotic proteins like Bcl-2 or Mcl-1 can shift the equilibrium of genius and against apoptotic proteins and make disease cells more helpless against cell death. [36]

- ✓ *Activation of Extrinsic Apoptotic Pathway:*

Death ligands, such as tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), attach to death receptors on the cell surface, starting the extrinsic apoptotic cascade. Activation methods for this pathway include:

- **Agonists of TRAIL receptors:** Through the activation of death receptors, TRAIL receptor agonists are created to imitate the effects of TRAIL and cause apoptosis. Bypassing resistance mechanisms, these agonists can specifically cause cancer cells to undergo apoptosis. [36]
- **Combination therapies:** Combining agents that activate the extrinsic pathway with other treatments, such as chemotherapy or radiation therapy, can enhance the apoptotic response. For example, combining TRAIL receptor agonists with conventional chemotherapeutic drugs can synergistically induce apoptosis and overcome resistance. [36, 37]

## V. TARGETING HYPOXIA

In cancer therapy, targeting hypoxia has emerged as a crucial tactic. Hypoxia is described by low levels of oxygen

in cancer tissues and is known to add to treatment obstruction, growth progression, and ominous patient results. [37]

➤ *Here are Some Approaches for Targeting Hypoxia in Cancer:*

• *Oxygen Delivery:*

Enhancing oxygen supply to hypoxic tumor regions can help overcome treatment resistance. Several methods are being explored to increase oxygen levels, including:

✓ *Hyperbaric Oxygen Therapy (HBOT):*

HBOT involves exposing patients to high-pressure oxygen environments. This can increase oxygen levels in hypoxic tissues, improving treatment response.[38]

✓ *Hemoglobin-Based Oxygen Carriers:*

Manufactured oxygen-conveying specialists called hemoglobin-based oxygen transporters can deliver oxygen directly to growth tissues. [37]

✓ *Modulation of Hypoxia-Inducible Factor (HIF) Pathway:*

The way cells respond to hypoxia is to a great extent constrained by transcriptional re-gulators known as hypoxia-inducible variables (HIFs). Focusing on the HIF pathway can affect different parts of growth science. Different strategies:

✓ *Inhibiting HIF-1 $\alpha$ :*

HIF-1 $\alpha$  is an imperative piece of the HIF pathway and plays an essential job in directing hypoxia responses. Blocking this component can effectively lower hypoxia-driven gene expression, which can lessen adaptive mechanisms within cancer cells. [39, 40]

✓ *Targeting Downstream HIF-Regulated Pathways:*

HIFs regulate numerous genes related to angiogenesis, metabolism, and cell survival. Under hypoxic conditions, targeting downstream effectors of HIF signaling pathways can limit tumor growth and survival. One effective approach is inhibiting factors like VEGF or glucose transporters. [41, 42]

• *Hypoxia-Activated Prodrugs:*

Hypoxia-activated prodrugs are specifically designed with the intent of lying dormant in areas rich with oxygen but, once they detect a deficiency in oxygen levels, their cytotoxic properties activate. These prodrugs can selectively target and kill hypoxic tumor cells while sparing oxygenated normal tissues. [43, 44]

➤ *Benefits of Nanoparticle Therapy for Cancer: [45, 46]*

Nanoparticles have shown significant advantages because of their special qualities and talents, in cancer therapy. Here are some of the key advantages:

• *Enhanced Drug Delivery:*

Nanoparticles can serve as carriers for delivering anti-cancer drugs to tumor sites. Their small size allows them to penetrate the tumor tissue more effectively, improving drug accumulation in the tumor and reducing off-target effects. Additionally, nanoparticle surface modifications can enable

targeted delivery to cancer cells while minimizing damage to healthy tissues. [47, 48]

• *Controlled Drug Release:*

Nanoparticles can be designed to release medicine in a targeted and regulated way. By enveloping medication within tiny particles, scientists can create systems that gradually release the drug or control its dispensation according to specific cues such as changes in temperature, pH level or enzyme activity. This controlled delivery upgrades the remedial adequacy and decreases drug poisonousness. [49, 50]

• *Overcoming Drug Resistance:*

Nanoparticles can assist with conquering drug obstruction generally saw in disease treatment. By exemplifying various medications inside a solitary nanoparticle or consolidating drug blends, nanoparticles can target different cell pathways engaged with drug obstruction all the while. This approach improves the probability of killing malignant growth cells and decreases the possibility creating obstruction.[51, 52]

• *Multimodal Imaging:*

Nanoparticles can be intended to have imaging abilities, considering painless perception of growths. [53, 54]

• *Combination Therapy:*

Nanoparticles give a stage to blend treatment, where different restorative specialists, like medications, qualities, or insusceptible invigorating particles, can be integrated inside a solitary nanoparticle framework. [55, 56]

• *Personalized Medicine:*

Nanoparticles offer open doors for customized medication in malignant growth treatment. They can be custom-made to individual patients by consolidating explicit focusing on ligands, biomarkers, or surface adjustments. [57, 58]

• *Minimizing Systemic Toxicity:*

By explicitly conveying medications to cancer destinations, nanoparticles lessen foundational poisonousness related with traditional chemotherapy. This targeted approach minimizes damage to healthy tissues, leading to improved patient tolerance and quality of life during treatment. [59, 60]

• *Major Barriers in the Clinical Application of Nanoparticles:*

Nanoparticles hold tremendous potential for a range of clinical applications. However, there are several critical issues that require resolution before their successful implementation in clinical practice. Some of the main challenges include: [40, 41]

✓ *Safety Concerns:*

Ensuring the safety of nanoparticle based therapeutics remains a crucial matter due to its substantial concerns and potential risks. Nanoparticles may interact with biological systems in complex ways and can potentially induce toxic

effects. Understanding the long-term biocompatibility, biodistribution, and potential accumulation of nanoparticles in various organs is crucial for assessing their safety profiles. [61, 62]

✓ *Regulatory Hurdles:*

The regulatory environment encompassing therapies dependent on nanoparticles keeps evolving. This implies that particular requirements and directives need fulfillment for clinical utilization. Before nanoparticle-based drugs or

remedies gain approval, comprehensive research has to be conducted regarding their efficacy, safety aspects as well as manufacturing uniformity resulting in prolonged processing timelines accompanied by steep costs. [63]

✓ *Scale-Up and Manufacturing:*

The manufacturing and scale-up of nanoparticles for clinical applications can be challenging. Maintaining batch-to-batch consistency, scalability, and costeffectiveness of nanoparticle production are critical considerations. [64, 65]




Fig 3 Nanoparticle Strategies to Overcome Cancer Drug Resistance

The continuous accomplishment of crafting durable and adaptable manufacturing processes with simultaneous attention to maintaining product excellence and consistency is a persistent challenge.

• *Pharmacokinetics and Biodistribution:*

Nanoparticles can manifest a multitude of distinct pharmacokinetic and biodistribution profiles that differ based on multiple factors comprising size, composition surface properties as well as administration methodology. Maximizing nanoparticle-based therapies necessitates a comprehensive knowledge base of how these tiny particles interact with biological barriers like the immune system while spreading through the body appropriately. [66, 67]

• *Targeting Efficiency:*

Achieving efficient and specific targeting of nanoparticles to the desired sites within the body remains a challenge. While nanoparticle surface modifications can enhance targeting to cancer cells or specific tissues, factors such as heterogeneity in target expression, barriers to nanoparticle penetration, and clearance mechanisms can limit their effective accumulation at the intended site. [68, 69]

• *Long-Term Stability:*

Nanoparticles might go through physical and synthetic changes over the long run, influencing their soundness and execution. Factors like total, corruption, and loss of helpful payload can influence the viability and security of nanoparticle-based treatments. Guaranteeing long haul

security under physiological circumstances is pivotal for their clinical application. [70]

• *Immunological Responses:*

Nanoparticles can trigger immune responses in the body, leading to potential adverse effects or reduced therapeutic efficacy. Immune reactions, such as inflammation or antibody response against nanoparticles, can affect their biodistribution, clearance, and therapeutic outcome. [71, 72]

## VI. CONCLUSION

In conclusion, nanoparticle-based therapies hold immense potential in revolutionizing cancer treatment. They offer advantages such as enhanced drug delivery, controlled drug release, the ability to overcome drug resistance, and multimodal imaging. Nanoparticles also provide opportunities for personalized medicine, minimizing systemic toxicity, and enabling combination therapies. The possibilities opened up by nanoparticle-based cancer treatments offer tremendous potential for improving patient outcomes. However, accomplishing this requires focused attention on several significant challenges such as ensuring robust safety measures are established throughout development stages; navigating complex regulatory landscapes; building scalable manufacturing processes while preserving quality assurance protocols; along with improving optimization targets for better outcomes efficiently. Future advances in this area can only be achieved through sustained research endeavors paired with sufficient investments towards meeting these challenges head-on. Here are some key perspectives:

➤ *Safety Optimization:*

A further in depth study is essential for us to understand comprehensively the long term nanoparticle safety profiles fully. It requires complete analysis of its interaction with the body's immune system, potential toxicity risks and high level examination on its compatibility with bio platforms. For attaining greater biosafety standards creating smarter designs using nanotechnology that prioritize higher degrees of controlled biodissolution and reduced dispersion can go a long way in reducing any adverse effects associated with these particles' use.

➤ *Targeting Strategies:*

Advancing nanoparticle targeting strategies will enhance their specificity and efficacy. This involves developing more precise and effective targeting ligands, utilizing biomarkers, and optimizing surface modifications to facilitate targeted delivery to cancer cells while avoiding healthy tissues.

➤ *Combination Therapies:*

Exploring synergistic combinations of therapeutics within nanoparticle systems can improve treatment outcomes. Integrating chemotherapy agents, immunotherapeutics, nucleic acids, or other modalities in a controlled and targeted manner can enhance the efficacy of cancer therapy and address the challenges of drug resistance.

➤ *Personalized Nanomedicine:*

Advancements in nanotechnology and personalized medicine can be synergistic. By tailoring nanoparticles to individual patients, based on their specific tumor characteristics and genetic profiles, personalized nanomedicine can be achieved. This approach would enable precise and effective treatment strategies, improving patient outcomes.

➤ *Integration of Nanotheranostics:*

Nanotheranostics, the combination of therapeutics and diagnostics within nanoparticles, hold tremendous potential. By integrating imaging agents and therapeutic payloads into a single nanoparticle system, simultaneous diagnosis, treatment, and monitoring of cancer can be achieved, leading to more personalized and effective therapeutic approaches.

## REFERENCES

- [1]. R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2020," *CA: A Cancer J. Clin.*, vol. 70, no. 1, pp. 7-30, Jan. 2020. DOI: <https://doi.org/10.3322/caac.21590>
- [2]. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation," *Cell*, vol. 144, no. 5, pp. 646-674, Mar. 2011. DOI: <https://doi.org/10.1016/j.cell.2011.02.013>
- [3]. B. Vogelstein et al., "Cancer genome landscapes," *Science*, vol. 339, no. 6127, pp. 1546-1558, Mar. 2013. DOI: <https://doi.org/10.1126/science.1235122>
- [4]. J. A. Joyce and D. T. Fearon, "T cell exclusion, immune privilege, and the tumor microenvironment," *Science*, vol. 348, no. 6230, pp. 74-80, Apr. 2015. DOI: <https://doi.org/10.1126/science.aaa6204>
- [5]. O. C. Farokhzad and R. Langer, "Impact of nanotechnology on drug delivery," *ACS Nano*, vol. 3, no. 1, pp. 16-20, Jan. 2009. DOI: <https://doi.org/10.1021/nn900002m>
- [6]. Y. Matsumura and H. Maeda, "A new concept for macromolecular therapeutics in tumor targeted solid tumor therapy: mechanism of tumor-tropic accumulation of proteins and the antitumor agent smancs," *Cancer Res.*, vol. 46, no. 12, pp. 6387-6392, Dec. 1986. DOI: <https://doi.org/10.1007/BF02996366>
- [7]. H. Maeda, "The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting," *Adv. Enzyme Regul.*, vol. 41, pp. 189-207, 2001. DOI: [https://doi.org/10.1016/s0065-2571\(00\)00013-3](https://doi.org/10.1016/s0065-2571(00)00013-3)
- [8]. N. Bertrand, J. Wu, X. Xu, N. Kamaly, and O. C. Farokhzad, "Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology," *Adv. Drug Deliv. Rev.*, vol. 66, pp. 2-25, Feb. 2014. DOI: <https://doi.org/10.1016/j.addr.2013.11.009>
- [9]. D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, and R. Langer, "Nanocarriers as an emerging platform for cancer therapy," *Nat. Nanotechnol.*, vol. 2, no. 12, pp. 751-760, Dec. 2007. DOI: <https://doi.org/10.1038/nnano.2007.387>

- [10]. S. K. Nune, P. Gunda, P. K. Thallapally, Y.-Y. Lin, M. L. Forrest, and C. J. Berkland, "Nanoparticles for biomedical imaging," *Expert Opin. Drug Deliv.*, vol. 6, no. 11, pp. 1175-1194, Nov. 2009. DOI: <https://doi.org/10.1517/17425240903229031>
- [11]. J. D. Byrne, T. Betancourt, and L. Brannon-Peppas, "Active targeting schemes for nanoparticle systems in cancer therapeutics," *Adv. Drug Deliv. Rev.*, vol. 60, no. 15, pp. 1615-1626, Dec. 2008. DOI: <https://doi.org/10.1016/j.addr.2008.08.005>
- [12]. R. Bazak, M. Hourri, S. El Achy, S. Kamel, and T. Refaat, "Cancer active targeting by nanoparticles: a comprehensive review of literature," *J. Cancer Res. Clin. Oncol.*, vol. 141, no. 5, pp. 769-784, May 2015. DOI: <https://doi.org/10.1007/s0432-014-1767-3>
- [13]. E. Blanco, H. Shen, and M. Ferrari, "Principles of nanoparticle design for overcoming biological barriers to drug delivery," *Nat. Biotechnol.*, vol. 33, no. 9, pp. 941-951, Sep. 2015. DOI: <https://doi.org/10.1038/nbt.3330>
- [14]. V. V. Mody, R. Siwale, A. Singh, and H. R. Mody, "Introduction to metallic nanoparticles," *J. Pharm. Bioallied Sci.*, vol. 2, no. 4, pp. 282-289, Oct. 2010. DOI: <https://doi.org/10.4103/0975-7406.68499>
- [15]. S. Irvani, "Green synthesis of metal nanoparticles using plants," *Green Chem.*, vol. 13, no. 10, pp. 2638-2650, 2011. DOI: <https://doi.org/10.1039/C1GC15386B>
- [16]. K. S. Soppimath, T. M. Aminabhavi, A. R. Kulkarni, and W. E. Rudzinski, "Biodegradable polymeric nanoparticles as drug delivery devices," *J. Control. Release*, vol. 70, no. 1-2, pp. 1-20, Jan. 2001. DOI: [https://doi.org/10.1016/S0168-3659\(00\)00339-4](https://doi.org/10.1016/S0168-3659(00)00339-4)
- [17]. N. Kamaly, B. Yameen, J. Wu, and O. C. Farokhzad, "Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release," *Chem. Rev.*, vol. 116, no. 4, pp. 2602-2663, Feb. 2016. DOI: <https://doi.org/10.1021/acs.chemrev.5b00346>
- [18]. A. Crintea et al., "Dendrimers: Advancements and Potential Applications in Cancer Diagnosis and Treatment—An Overview," *Pharmaceutics*, vol. 15, no. 5, p. 1406, May 2023. DOI: <https://doi.org/10.3390/pharmaceutics15051406>
- [19]. U. Boas and P. M. Heegaard, "Dendrimers in drug research," *Chem. Soc. Rev.*, vol. 33, no. 1, pp. 43-63, Jan. 2004. DOI: <https://doi.org/10.1039/B309043B>
- [20]. A. M. Wu and P. D. Senter, "Arming antibodies: prospects and challenges for immunoconjugates," *Nat. Biotechnol.*, vol. 23, no. 9, pp. 1137-1146, Sep. 2005. DOI: <https://doi.org/10.1038/nbt1141>
- [21]. J. M. Reichert, C. J. Rosensweig, L. B. Fenge, and W. E. Pierce, "Monoclonal antibody successes in the clinic," *Nat. Biotechnol.*, vol. 23, no. 9, pp. 1073-1078, Sep. 2005. DOI: <https://doi.org/10.1038/nbt0905-1073>
- [22]. T. M. Allen and P. R. Cullis, "Liposomal drug delivery systems: from concept to clinical applications," *Adv. Drug Deliv. Rev.*, vol. 65, no. 1, pp. 36-48, Jan. 2013. DOI: <https://doi.org/10.1016/j.addr.2012.09.037>
- [23]. M. D. Fulton and W. Najahi-Missaoui, "Liposomes in Cancer Therapy: How Did We Start and Where Are We Now," *Int. J. Mol. Sci.*, vol. 24, no. 7, p. 6615, Apr. 2023. DOI: <https://doi.org/10.3390/ijms24076615>
- [24]. W. J. Stark, "Nanoparticles in biological systems," *Angew. Chem. Int. Ed.*, vol. 50, no. 6, pp. 1242-1258, Feb. 2011. DOI: <https://doi.org/10.1002/anie.200906684>
- [25]. L. Zhang, F. X. Gu, J. M. Chan, A. Z. Wang, R. S. Langer, and O. C. Farokhzad, "Nanoparticles in medicine: therapeutic applications and developments," *Clin. Pharmacol. Ther.*, vol. 83, no. 5, pp. 761-769, May 2008. DOI: <https://doi.org/10.1038/sj.cpt.6100400>
- [26]. H. Wang, K. Zhuang, and B. S. Leong, "Carbon nanomaterials for biological imaging and nanomedicinal therapy," *Chem. Rev.*, vol. 113, no. 5, pp. 3407-3424, May 2013. DOI: <https://doi.org/10.1021/cr300307s>
- [27]. Z. Liu, J. T. Robinson, S. M. Tabakman, K. Chen, and H. Dai, "Carbon materials for drug delivery & cancer therapy," *Mater. Today*, vol. 14, no. 7-8, pp. 316-323, Jul. 2011. DOI: [https://doi.org/10.1016/S1369-7021\(11\)70161-4](https://doi.org/10.1016/S1369-7021(11)70161-4)
- [28]. I. L. Medintz, H. T. Uyeda, E. R. Goldman, and H. Mattoussi, "Quantum dot bioconjugates for imaging, labelling and sensing," *Nat. Mater.*, vol. 4, no. 6, pp. 435-446, Jun. 2005. DOI: <https://doi.org/10.1038/nmat1390>
- [29]. A. M. Smith, X. Gao, and S. Nie, "Quantum dot nanocrystals for in vivo imaging and cancer molecular detection," *Photochem. Photobiol.*, vol. 80, no. 3, pp. 377-385, Nov. 2004. DOI: <https://doi.org/10.1111/j.1751-1097.2004.tb00096.x>
- [30]. Q. A. Pankhurst, J. Connolly, S. K. Jones, and J. Dobson, "Applications of magnetic nanoparticles in biomedicine," *J. Phys. D: Appl. Phys.*, vol. 36, no. 13, pp. R167-R181, Jun. 2003. DOI: <https://doi.org/10.1088/0022-3727/36/13/201>
- [31]. A. K. Gupta and M. Gupta, "Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications," *Biomaterials*, vol. 26, no. 18, pp. 3995-4021, Jun. 2005. DOI: <https://doi.org/10.1016/j.biomaterials.2005.02.009>
- [32]. S. V. Dorozhkin, "Calcium orthophosphates in nature, biology and medicine," *Materials*, vol. 2, no. 2, pp. 399-498, Apr. 2009. DOI: <https://doi.org/10.3390/ma2020399>
- [33]. M. Eppe et al., "Application of calcium phosphate nanoparticles in biomedicine," *J. Mater. Chem.*, vol. 20, no. 1, pp. 18-23, 2010. DOI: <https://doi.org/10.1039/B910885H>
- [34]. M. M. Gottesman, "Mechanisms of cancer drug resistance," *Annu. Rev. Med.*, vol. 53, pp. 615-627, 2002. DOI: <https://doi.org/10.1146/annurev.med.53.082901.103929>
- [35]. G. Szakács, J. K. Paterson, J. A. Ludwig, C. Booth-Genthe, and M. M. Gottesman, "Targeting multidrug resistance in cancer," *Nat. Rev. Drug Discov.*, vol. 5,

- no. 3, pp. 219-234, Mar. 2006. DOI: <https://doi.org/10.1038/nrd1984>
- [36]. R. S. Wong, "Apoptosis in cancer: from pathogenesis to treatment," *J. Exp. Clin. Cancer Res.*, vol. 30, no. 1, p. 87, Sep. 2011. DOI: <https://doi.org/10.1186/1756-9966-30-87>
- [37]. A. L. Harris, "Hypoxia—a key regulatory factor in tumour growth," *Nat. Rev. Cancer*, vol. 2, no. 1, pp. 38-47, Jan. 2002. DOI: <https://doi.org/10.1038/nrc704>
- [38]. M. W. Dewhirst, Y. Cao, and B. Moeller, "Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response," *Nat. Rev. Cancer*, vol. 8, no. 6, pp. 425-437, Jun. 2008. DOI: <https://doi.org/10.1038/nrc2397>
- [39]. G. L. Semenza, "Hypoxia-inducible factors in physiology and medicine," *Cell*, vol. 148, no. 3, pp. 399-408, Feb. 2012. DOI: <https://doi.org/10.1016/j.cell.2012.01.021>
- [40]. P. Carmeliet and R. K. Jain, "Angiogenesis in cancer and other diseases," *Nature*, vol. 407, no. 6801, pp. 249-257, Sep. 2000. DOI: <https://doi.org/10.1038/35025220>
- [41]. D. Liang, G. H. Miller, and G. K. Tranmer, "Hypoxia Activated Prodrugs: Factors Influencing Design and Development," *Curr. Med. Chem.*, vol. 22, no. 37, pp. 4313-4325, 2015. DOI: <https://doi.org/10.2174/0929867322666151021111016>
- [42]. N. Baran and M. Konopleva, "Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy," *Clin. Cancer Res.*, vol. 23, no. 10, pp. 2382-2390, May 2017. DOI: <https://doi.org/10.1158/1078-0432.CCR-16-0895>
- [43]. J. M. Brown and W. R. Wilson, "Exploiting tumour hypoxia in cancer treatment," *Nat. Rev. Cancer*, vol. 4, no. 6, pp. 437-447, Jun. 2004. DOI: <https://doi.org/10.1038/nrc1367>
- [44]. C. P. Guise et al., "Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia," *Chin. J. Cancer*, vol. 33, no. 2, pp. 80-86, Feb. 2014. DOI: <https://doi.org/10.5732/cjc.012.10205>
- [45]. J. Shi, P. W. Kantoff, R. Wooster, and O. C. Farokhzad, "Cancer nanomedicine: progress, challenges and opportunities," *Nat. Rev. Cancer*, vol. 17, no. 1, pp. 20-37, Jan. 2017. DOI: <https://doi.org/10.1038/nrc.2016.108>
- [46]. S. R. D'Mello, C. N. Cruz, A. Q. Chen, M. Kapoor, S. L. Lee, and A. S. Woods, "The evolving landscape of drug products containing nanomaterials in the United States," *Nat. Nanotechnol.*, vol. 12, no. 6, pp. 523-529, Jun. 2017. DOI: <https://doi.org/10.1038/nnano.2017.67>
- [47]. S. Mura, J. Nicolas, and P. Couvreur, "Stimuli-responsive nanocarriers for drug delivery," *Nat. Mater.*, vol. 12, no. 11, pp. 991-1003, Nov. 2013. DOI: <https://doi.org/10.1038/nmat3776>
- [48]. R. A. Petros and J. M. DeSimone, "Strategies in the design of nanoparticles for therapeutic applications," *Nat. Rev. Drug Discov.*, vol. 9, no. 8, pp. 615-627, Aug. 2010. DOI: <https://doi.org/10.1038/nrd2591>
- [49]. T. M. Allen and P. R. Cullis, "Drug delivery systems: entering the mainstream," *Science*, vol. 303, no. 5665, pp. 1818-1822, Mar. 2004. DOI: <https://doi.org/10.1126/science.1095833>
- [50]. M. El-Sayed and A. S. Hoffman, "The use of smart polymers in delivering drugs," *Expert Opin. Biol. Ther.*, vol. 5, no. 1, pp. 23-32, Jan. 2005. DOI: <https://doi.org/10.1517/14712598.5.1.23>
- [51]. Y. Yao et al., "Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance," *Front. Mol. Biosci.*, vol. 7, p. 193, Sep. 2020. DOI: <https://doi.org/10.3389/fmolb.2020.00193>
- [52]. K. M. L. Taylor-Pashow, J. Della Rocca, Z. Xie, S. Tran, and W. Lin, "Postsynthetic modifications of iron-carboxylate nanoscale metal-organic frameworks for imaging and drug delivery," *J. Am. Chem. Soc.*, vol. 131, no. 40, pp. 14261-14263, Oct. 2009. DOI: <https://doi.org/10.1021/ja906198y>
- [53]. C. H. Choi et al., "Multimodal imaging and therapy of cancer with nanoscale particles," *Expert Opin. Drug Deliv.*, vol. 9, no. 7, pp. 781-797, Jul. 2012. DOI: <https://doi.org/10.1517/17425240.2012.688053>
- [54]. S. K. Nune et al., "Nanoparticles for biomedical imaging," *Expert Opin. Drug Deliv.*, vol. 6, no. 11, pp. 1175-1194, Nov. 2009. DOI: <https://doi.org/10.1517/17425240903229031>
- [55]. C. M. Hu, L. Zhang, S. Aryal, C. Cheung, R. H. Fang, and L. Zhang, "Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform," *Proc. Natl. Acad. Sci. U.S.A.*, vol. 108, no. 27, pp. 10980-10985, Jul. 2011. DOI: <https://doi.org/10.1073/pnas.1106634108>
- [56]. Y. Zhang, M. R. K. Ali, E. Oyelere, B. Hondroulis, and M. A. El-Sayed, "Multiplexing therapeutics for the treatment of cancer," *Bioconjug. Chem.*, vol. 27, no. 1, pp. 1-13, Jan. 2016. DOI: <https://doi.org/10.1021/acs.bioconjchem.5b00424>
- [57]. A. Z. Wang, R. Langer, and O. C. Farokhzad, "Nanoparticle delivery of cancer drugs," *Annu. Rev. Med.*, vol. 63, pp. 185-198, Feb. 2012. DOI: <https://doi.org/10.1146/annurev-med-040210-162544>
- [58]. S. S. Kelkar and T. M. Reineke, "Theranostics: combining imaging and therapy," *Biomacromolecules*, vol. 12, no. 6, pp. 187-200, Jun. 2011. DOI: <https://doi.org/10.1021/bm2004068>
- [59]. D. T. Wiley, P. Webster, A. Gale, and M. E. Davis, "Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor," *Proc. Natl. Acad. Sci. U.S.A.*, vol. 110, no. 21, pp. 8662-8667, May 2013. DOI: <https://doi.org/10.1073/pnas.1307152110>
- [60]. A. M. Gobin, M. H. Lee, N. J. Halas, W. D. James, R. A. Drezek, and J. L. West, "Near-infrared resonant nanoshells for combined optical imaging and photothermal cancer therapy," *Nano Lett.*, vol. 7, no. 7, pp. 1929-1934, Jul. 2007. DOI: <https://doi.org/10.1021/nl070610y>
- [61]. G. Oberdörster, E. Oberdörster, and J. Oberdörster, "Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles," *Environ. Health*

- Perspect., vol. 113, no. 7, pp. 823-839, Jul. 2005. DOI: <https://doi.org/10.1289/ehp.7339>
- [62]. A. Nel, T. Xia, L. Mädler, and N. Li, "Toxic potential of materials at the nanolevel," *Science*, vol. 311, no. 5761, pp. 622-627, Feb. 2006. DOI: <https://doi.org/10.1126/science.1114397>
- [63]. V. P. Torchilin, "Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery," *Nat. Rev. Drug Discov.*, vol. 13, no. 11, pp. 813-827, Nov. 2014. DOI: <https://doi.org/10.1038/nrd4333>
- [64]. S. H. Bawa, P. F. Bawa, W. E. Maude, and A. Bawa, "Regulatory hurdles in clinical translation of nanomedicine," *J. Control. Release*, vol. 125, no. 3, pp. 165-171, Feb. 2008. DOI: <https://doi.org/10.1016/j.jconrel.2007.10.024>
- [65]. J. Hrkach et al., "Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile," *Sci. Transl. Med.*, vol. 4, no. 128, p. 128ra39, Apr. 2012. DOI: <https://doi.org/10.1126/scitranslmed.3003651>
- [66]. W. H. De Jong and P. J. Borm, "Drug delivery and nanoparticles: applications and hazards," *Int. J. Nanomedicine*, vol. 3, no. 2, pp. 133-149, 2008. DOI: <https://doi.org/10.2147/ijn.s596>
- [67]. S. Mitragotri, P. A. Burke, and S. MacMillan, "Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies," *Nat. Rev. Drug Discov.*, vol. 13, no. 9, pp. 655-672, Sep. 2014. DOI: <https://doi.org/10.1038/nrd4363>
- [68]. P. J. G. Gout et al., "Nanocarriers for cancer therapy: pharmacokinetic and biodistribution perspectives," *J. Pharm. Sci.*, vol. 101, no. 3, pp. 860-880, Mar. 2012. DOI: <https://doi.org/10.1002/jps.22851>
- [69]. E. Ruoslahti, S. N. Bhatia, and M. J. Sailor, "Targeting of drugs and nanoparticles to tumors," *J. Cell Biol.*, vol. 188, no. 6, pp. 759-768, Mar. 2010. DOI: <https://doi.org/10.1083/jcb.200910104>
- [70]. V. P. Torchilin, "Targeted pharmaceutical nanocarriers for cancer therapy and imaging," *AAPS J.*, vol. 9, no. 2, pp. E128-E147, May 2007. DOI: <https://doi.org/10.1208/aapsj0902015>
- [71]. M. A. Dobrovolskaia and S. E. McNeil, "Immunological properties of engineered nanomaterials," *Nat. Nanotechnol.*, vol. 2, no. 8, pp. 469-478, Aug. 2007. DOI: <https://doi.org/10.1038/nnano.2007.223>
- [72]. S. E. A. Gratton et al., "The effect of particle design on cellular internalization pathways," *Proc. Natl. Acad. Sci. U.S.A.*, vol. 105, no. 33, pp. 11613-11618, Aug. 2008. DOI: <https://doi.org/10.1073/pnas.0801763105>